



Impact of Visceral Obesity and Plasma Apelin Level on Coronary Artery Disease in Egyptian Patients

Thesis

Submitted for Partial Fulfillment of Master Degree in
Cardiology

By

Mutaz Rahman Alkhnifsawi
M.B.B.Ch (Iraq)

Under Supervision of

Dr. Azza Farrag ; M.D
Professor of Cardiology
Faculty of Medicine, Cairo University

Dr. Karim Saied Mostafa ; M.D
Assistant Professor of Cardiology
Faculty of Medicine, Cairo University

Dr. Bassem El Zarif ; M.D
Consultant of Cardiology
National Heart Institute, Cairo University

Faculty of Medicine
Cairo University
2013

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

(وَفَوْقَ كُلِّ ذِي عِلْمٍ عَلِيمٌ)

صدق الله العظيم

(سورة يوسف الآية 76)

ABSTRACT

Background: Distribution of body fat is known to be more independent and potent predictor of morbidity and mortality than total body adiposity, individuals with abdominal obesity are at a great risk for developing type 2 diabetes mellitus and atherosclerotic cardiovascular disease. Apelin could be considered a 'good' adipokine when considering cardiovascular disease. It reduces atherogenesis, macrophage inflammation, mean arterial pressure, cardiomyocyte contractility, atrial fibrillation and heart failure.

Objectives: To assess the impact of visceral obesity and plasma level of apelin on coronary artery disease in Egyptian patients.

Patients and methods: A total of 371 patients were recruited in this observational study, mean age was (53.6± 9), males were 229(61.7%) and 142(38.3%) were females scheduled for elective coronary angiography in Kaser alainy teaching hospital and national heart institute for the period between December 2012 and May 2013. All patients were subjected to thorough history taking including sex, history of smoking, diabetes, hypertension and family history of coronary artery disease, reason for coronary angiography and any previous history of peripheral vascular disease, myocardial infarction , congestive heart failure, chronic obstructive pulmonary disease, analysis of lipid profile, measurement of serum creatinine and fasting plasma glucose, plasma level of apelin standard transthoracic echocardiogram, as well as measurement of body mass index, waist circumference, waist hip ratio and waist height ratio. Obesity was defined as body mass index ≥ 30 kg/m², waist circumference ≥ 94 cm for men and ≥ 80 cm for women, waist height ratio ≥ 0.5 and waist hip ratio ≥ 0.85 in females and ≥ 0.90 in males.

Results: There was no significant difference between obese and non obese patients as regarding Gensini score ,most probably due to small sample size . Plasma apelin level did not show significant difference between groups. Body mass index correlated significantly with total cholesterol ($r=0.140$, $p=0.012$) and with LDL-C ($r=0.132$, $p= 0.018$) , body mass index was also correlated with plasma apelin level ($r=0.232$, $p= 0.039$) , waist circumference correlated significantly with total cholesterol ($r = 0.150$, $P= 0.007$) , waist height ratio correlated significantly with total cholesterol ($r = 0.183$, $p= 0.001$) and with LDL-C ($r = 0.140$, $p= 0.012$)

Conclusion: We concluded in our study that there no difference was found in plasma apelin between obese and non obese patients and no correlation between apelin and Gensini score. Also females was predominant in obese group. There was an increase in cardiovascular risk factors among obese Egyptian patients .

Keywords: Visceral obesity, Apelin, Coronary artery disease

Acknowledgements

Glory to Allah, The Most Beneficent and Most Merciful, and to His Beloved Prophet Mohammed (Peace be upon Him).

*I would like to express my gratitude to **Prof. Azza Farrag**, Professor of cardiology, Cairo university, for being an outstanding advisor and excellent professor. Her constant encouragement, support, and invaluable suggestions made this work a valuable one.*

*I would like to express my deep gratitude, appreciation and sincere thanks to **Dr. Kareem Said**, assistant Professor of cardiology, Cairo university, for his supervision, valuable remarks, until this work was fulfilled.*

*I would like to express my special deep gratitude, appreciation and sincere thanks to **Dr. Bassem El Zarif**, consultant cardiologist, national heart institute, for his unfailing support, meticulous supervision, great valuable remarks, encouragement and assistance until this work was fulfilled.*

*My appreciation goes also to **Prof. Amal Rizk**, Professor of clinical pathology, Cairo University for her contribution in this work,*

A special thanks goes to Dr Amal Al Haj cardiologist at Thawra generalized hospital , Sanaa, Yemen since our work was a continuation of her work and her collected cases were enrolled in our study population , as well as some of her literature was useful for us .

I am very grateful to all members of cardiology department, Cairo University, and national heart institute and particularly staff members of the catheterization laboratory for their help in completing this work.

Finally, I would like to express my special deep thanks and gratitude to my parents and wife who supported me along all years of my study.

LIST OF CONTENTS

	Page
Abbreviations	V
List of tables	VIII
List of figures	X
INTRODUCTION	1
AIM OF THE WORK	4
REVIEW OF LITERATURE:	
• CHAPTER I: Problem of Obesity	5
• CHAPTER II: Parameters of Obesity	28
• CHAPTER III: Abdominal Obesity and Coronary Artery Disease	41
• CHAPTER IV: Adipose Tissue and Apelin	51
METHODOLOGY	62
RESULTS	69
DISCUSSION	87
SUMMARY	94
STUDY LIMITATION	98
CONCLUSION	99
REFERENCES	100
MASTER Table	131
ARABIC Summary	

List of Abbreviations

ACS	Acute coronary syndrom
ADA	American Diabetes Association
Ang II	: Angiotensin II
APJ	: Apelin receptors
Apo	: Apoproteins
AT1	Angiotensin 1
ATP	: Adenosin triphosphate
AtRa	: Alltransretinoic acid
BIA	: Bioelectrical Impedance analysis
BMI	: Body mass index
CABG	: Coronary Artery by pass grafting
CAD	: Coronary artery disease
CAC	: Coronary artery calcium
CPAP	: Continuous positive airway pressure
CKD	: Chronic kidney disease
CT	: Computed tomography
CTA	: Computed tomography angiography
CVD	: Cardiovascular disease
CVS	: Cardiovascular stroke
DXA	: Dual energy X ray absorptimetry
ECG	: Electrocardiography
ELISA	: Enzyme linked immunosorbent assay
FEV1	: Forced expiratory volume in first second
FFA	: Free fatty acids
FPG	: Fasting plasma glucose
FRC	: Functional residual capacity
FVC	: Forced vital capacity
HDL	: High density lipoproteins
HTN	: Hypertension
IDF	: International diabetes federation
IL	: Interleukin

IR	: Insulin resistance
I/R	: Ischemia / reperfusion injury
LDL	: Low density lipoprotein
LVEF	: Left ventricular ejection fraction
MAP	: Mean arterial pressure
MCP 1	: Monocyte chemoattractant protein 1
MI	: Myocardial infarction
MPTP	: Mitochondrial Permeability Transition Pore
MRI	: Magnetic resonance imaging
NHANES	: National health and nutrition examination survey
NHP	: National hypertension project
NICE	National Institute for health and care excellence
NIDD	: Non insulin dependent diabetes mellitus
NO	: Nitric oxide
NOS	: Nitric oxide synthase
NYHA	: New York heart association
OSA	: Obstructive sleep apnea
PAI	: Plasminogen activator inhibitor
P _{crit}	: Critical closing pressure
PKC	: Phosphokinase C
PLC	: Phospholipase C
PVD	: Peripheral vascular disease
RAS	: Renin angiotensin system
RCA	: Right coronary artery
RISK	: Reperfusion injury salvage kinase
RV	: Residual volume
SES	: Socioeconomic status
SD	Standard Deviation
STEMI	: ST elevation myocardial Infarction
T1DM	: Type 1 diabetes mellitus
T2DM	: Type 2 diabetes mellitus
TLC	: Total lung capacity

TNF	:	Tumor necrosis factor
TTE	:	Tran thoracic echocardiography
UA	:	Unstable angina
US	:	Ultrasound
VFA	:	Visceral fat adepositiy
V/S	:	Visceral / subcutaneous
WAT	:	White adipose tissue
WC	:	Waist circumference
WHR	:	Waist hip ratio
WHO	:	World health organization
WHtR	:	Waist height ratio

LIST OF Tables

<i>Table No.</i>	<i>Title</i>	<i>Page No.</i>
1.	World health organization (WHO) classification of obesity (2000)	6
2.	Brief description of various methods to estimate body fat	35
3.	Abdominal obesity and heart disease : INTERHEART Study	42
4.	Demographic and clinical characteristics of the whole studied population	70
5.	Clinical characteristics of obese versus non obese patients classified according to BMI	71
6.	Laboratory data, EF and Gensini score of obese versus non obese patients classified according to BMI	72
7.	Clinical characteristics of obese versus non obese patients classified according to WHtR	73
8.	Laboratory data, EF , Gensini score of obese versus non obese patients classified according to WHtR	74
9.	Clinical characteristics of obese versus non obese patients classified according to WC (female patients)	75
10.	Laboratory data, EF, Gensinis score of obese versus non obese patients classified according to WC (female patients)	76
11.	Clinical characteristics of obese versus non obese patients classified according to WC (male patients)	77
12.	Laboratory data, EF, Gensinis score of obese versus non obese patients classified according to WC (male patients)	78
13.	Clinical characteristics of obese versus non obese patients classified according to WHR (female patients)	79
14.	Laboratory data, EF , Gensini score of obese versus non obese patients classified according to WHR (female patients)	80
15.	Clinical characteristics of obese versus non obese patients classified according to WHR (male patients)	81
16.	Laboratory data ,EF ,Gensini score of obese versus non obese patients classified according to WHR (male patients)	82
17.	Plasma apelin in obese and non obese according to BMI	84

18.	Plasma apelin in obese and non obese according to WHtR	84
19.	Plasma apelin in obese and non obese according to WC (male patients)	85
20.	Plasma apelin in obese and non obese according to WC (female patients)	85
21.	Plasma apelin in obese and non obese according to WHR (male patients) .	85
22.	Plasma apelin in obese and non obese according to WHR (female patients)	86

List of Figures

<i>Figure No.</i>	<i>Title</i>	<i>Page No.</i>
1.	Induction of insulin resistance and inflammation in obesity	18
2.	Adipose tissue products work directly at the vessel wall and through the liver to modulate the atherogenic environment of the vessel wall	23
3.	Waist circumference in NT Egyptians: Frequency Distribution. Source: Egyptian NHP (1991-1994)	39
4.	WC and age (mean) in Women. Source: Egyptian NHP (1991-1994)	40
5.	Survival was significantly better in the overweight and obese categories.	49
6.	Leptin and adiponectin: leptin acts primarily via the melanocortin system	52
7.	Physiological and pathophysiological roles of apelin.	59
8.	Gensini score system in assessment of the severity of coronary artery lesion .	67
9.	Correlation between BMI and apelin	83

INTRODUCTION

The beneficial impact on cardiovascular morbidity and mortality of favorable trends in population control of classic risk factors such as smoking, hypercholesterolemia, and hypertension may be reversed by the current epidemic of obesity⁽¹⁾. Obesity, in particular abdominal adiposity, is associated with increased risk of cardiovascular disease (CVD) and type 2 diabetes mellitus (T2DM)⁽²⁾.

Recent publications have shown that the overweight and particularly the obese have progressively higher morbidity and mortality⁽³⁾. The multinational INTERHEART case control study confirmed the importance of obesity, particularly abdominal adiposity, as a potent risk factor for myocardial infarction⁽⁴⁾.

Abdominal obesity, which reflects central body fat distribution, has been suggested as a better marker of the obesity risk⁽⁵⁾.

Excess visceral fat is important in the etiology of chronic diseases T2DM, hypertension, coronary artery diseases (CAD) given its association with circulating free fatty acids, insulin resistance (IR), hyperinsulinemia, dyslipidemia, and atherosclerotic inflammatory markers⁽⁶⁾.

Waist circumference (WC) and the waist hip ratio (WHR) are widely used as indicators of abdominal adiposity in epidemiologic studies. Compared with WHR, WC has been shown to be a better marker of visceral fat⁽⁷⁾ and correlates more strongly with CVD risk factors⁽⁸⁾. WHR has also been shown to be a good predictor of increased risk of T

2DM ⁽⁹⁾ and CAD ⁽¹⁰⁾ which may be due to attributes related to small hip relative to WC. Cross-sectional and prospective studies have found that when WC is taken into account, a larger hip circumference is associated with reduced risk factors for T2DM ⁽¹¹⁾ and CVD ⁽¹²⁾.

Abdominal obesity is also a significant risk factor for atherosclerosis.

Excessive accumulation of visceral fat is associated with IR and compensatory hyperinsulinemia, which contributes to atherosclerotic progression⁽¹³⁾.

CAD is the single leading cause of death in the United States, and accounted for 1 of every 6 deaths in 2009. Approximately 1.2 million people in the United States suffer a new or recurrent heart attack each year, and nearly half (47%) die before they receive emergency services⁽¹⁴⁾.

Apelin is a novel peptide that acts through the apelin receptors (APJ receptor), sharing similarities with the angiotensin II–angiotensin II type 1 receptor pathway. It is one of the adipokines secreted from human adipose tissue. It is a peripheral vasodilator, powerful inotrope and may affect central fluid homeostasis ⁽¹⁵⁾. In obese subjects, plasma apelin is about fivefold higher than it is in lean controls ⁽¹⁶⁾.

Most of the adipocytokines secreted by visceral fat reduce the visceral fat volume or normalize the visceral /subcutaneous ratio (V/S ratio), on the contrary, with a change in plasma adipocytokine level and imbalance among them in the body for a long term, it will become a

pathological condition and may contribute to the development of (IR) by various kinds of effects ⁽¹⁷⁾ .

Plasma apelin levels are lower in child obesity and pubertal state is an important determinant of plasma apelin levels ⁽¹⁸⁾ .

Apelin could be considered a ‘good’ adipokine when considering CVD. It reduces atherogenesis, macrophage inflammation, mean arterial pressure (MAP), cardiomyocyte contractility, atrial fibrillation and heart failure. It is cardioprotective, given that it reduces infarct size in I/R models, delaying mitochondrial permeability transition pore (MPTP) opening. Knockout studies demonstrate that the absence of apelin increases cardiac dysfunction. However, its role in ischemic heart disease and heart failure is not fully understood. The myocardial expression of apelin may differ from plasma levels, the conclusions from which are as yet unclear⁽¹⁹⁾. Further research is required in delineating its role in the myocardium in different pathologies.